ImmunoCellular Therapeutics, Ltd.(OTCBB: IMUC) a biotechnology company focused on the development of novel
immune-based cancer therapies, today announced that data from a recent clinical
trial of ICT-107, the company's dendritic cell based cancer vaccine candidate
for the treatment of glioblastoma multiforme (GBM), will be presented at the
46th Annual Meeting of the American Society of Clinical Oncology (ASCO) being
held June 4-8 in Chicago. The presentation, "Immune response correlation with
progression-free survival in glioblastoma following dendritic cell immunotherapy
(ICT-107)," features data showing ICT-107 provided a significant increase in
survival in patients who received the vaccine.
In the Phase I clinical study of ICT-107 in GBM, newly diagnosed patients who
received the vaccine in addition to the standard of care of surgery, radiation
and chemotherapy demonstrated a one year overall survival of 100 percent and a
two year survival of 80 percent. This compares favorably with historical 61.1
percent one-year and 26.5 percent two-year survival based on the standard of
care alone. The median overall survival has not yet been reached at the 26.4
months analysis point, with 12 out of 16 patients alive (75% percent).
The 12-month disease-free survival from the time of surgery was 75 percent with
ICT-107, compared with the historical control of 26.9 percent, and the 18-month
disease-free survival with ICT-107 was 49.2 percent, compared with 18.4 percent
historically. The median progression-free survival (PFS) of 17.7 months after
surgery compared especially favorably with the historical median PFS of 6.9
months observed with the standard treatment. Seven of the 16 patients (44
percent) who participated in the study continue to live with no disease
progression with an average time of over 29 months. Safety data for ICT-107 also
compared favorably to current treatments: no serious adverse events were
reported and minor side effects were limited to fatigue, skin rash and pruritis.
"These new data further establish ICT-107 as a promising potential treatment for
glioblastoma, a disease for which there are currently few and limited treatment
options," said Surasak Phuphanich, M.D., Director of the Neuro-Oncology Program
at Cedars-Sinai Medical Center. "We are excited for what these data mean for
patients, the medical community, and the field of immunotherapy as a whole. We
look forward to further investigating ICT-107 in additional clinical studies."
